Oncolytics Biotech (ONCY) to Release Earnings on Friday

Oncolytics Biotech (NASDAQ:ONCY) is expected to release its Q4 2025 results before the market opens on Friday, March 6th. Analysts expect Oncolytics Biotech to post earnings of ($0.06) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 13, 2026 at 5:00 PM ET.

Oncolytics Biotech Stock Up 1.9%

Shares of ONCY stock opened at $1.06 on Thursday. The stock’s 50-day moving average price is $1.00 and its 200 day moving average price is $1.08. The stock has a market capitalization of $112.52 million, a PE ratio of -3.79 and a beta of 0.92. Oncolytics Biotech has a 52-week low of $0.33 and a 52-week high of $1.51.

Insider Activity at Oncolytics Biotech

In related news, Director Wayne Pisano purchased 30,000 shares of the stock in a transaction dated Thursday, February 12th. The shares were acquired at an average cost of $0.84 per share, with a total value of $25,200.00. Following the purchase, the director directly owned 492,414 shares in the company, valued at $413,627.76. This trade represents a 6.49% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Patricia S. Andrews purchased 35,400 shares of the business’s stock in a transaction dated Thursday, February 12th. The stock was bought at an average price of $0.86 per share, with a total value of $30,444.00. Following the acquisition, the director directly owned 78,128 shares in the company, valued at approximately $67,190.08. This represents a 82.85% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 389,232 shares of company stock valued at $348,084 over the last 90 days. Company insiders own 0.10% of the company’s stock.

Institutional Investors Weigh In On Oncolytics Biotech

Hedge funds and other institutional investors have recently modified their holdings of the stock. Citadel Advisors LLC purchased a new stake in shares of Oncolytics Biotech during the 3rd quarter worth approximately $535,000. XTX Topco Ltd acquired a new position in Oncolytics Biotech during the fourth quarter worth $69,000. Virtu Financial LLC purchased a new stake in Oncolytics Biotech during the fourth quarter worth $68,000. Tocqueville Asset Management L.P. acquired a new stake in Oncolytics Biotech in the fourth quarter valued at $63,000. Finally, CIBC Private Wealth Group LLC purchased a new position in shares of Oncolytics Biotech in the fourth quarter valued at $44,000. 6.82% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Wall Street Zen cut Oncolytics Biotech from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Oncolytics Biotech in a research note on Monday, December 29th. Finally, HC Wainwright raised their target price on shares of Oncolytics Biotech from $5.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday, November 17th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $6.25.

About Oncolytics Biotech

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.